{"id":"anti-angiogenesis","safety":{"commonSideEffects":[{"rate":"20%","effect":"Fatigue"},{"rate":"15%","effect":"Headache"},{"rate":"10%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Anti-angiogenesis drugs like this one work by blocking the action of VEGF, a protein that promotes the formation of new blood vessels. This can help slow the growth of tumors and reduce the risk of metastasis.","oneSentence":"Inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF)","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:34:22.016Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of various cancers"}]},"trialDetails":[{"nctId":"NCT07470840","phase":"PHASE2","title":"SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2027-02-01","conditions":"Locally Advanced or Metastatic Renal Cell Carcinoma","enrollment":27},{"nctId":"NCT07488533","phase":"PHASE2","title":"Comparing the Combination of Sullumab and Fruquintinib in Postoperative Adjuvant Therapy for High Recurrence Risk Non Transparent Renal Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-08-01","conditions":"Non-Clear Cell Renal Cell Carcinoma","enrollment":40},{"nctId":"NCT07488572","phase":"PHASE2","title":"Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study","status":"ENROLLING_BY_INVITATION","sponsor":"Sun Yat-sen University","startDate":"2025-11-01","conditions":"Renal Cell Carcinoma (RCC), Metastatic Clear Cell Renal Cell Carcinoma","enrollment":60},{"nctId":"NCT07320963","phase":"PHASE1, PHASE2","title":"Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-31","conditions":"Nasopharyngeal Carcinoma","enrollment":52},{"nctId":"NCT03185039","phase":"NA","title":"Predictive Impact of MMP2 and MMP9 Levels for Patients With Metastatic Kidney Cancer Treated With Anti-angiogenic Agents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut Paoli-Calmettes","startDate":"2017-05-29","conditions":"Kidney Cancer","enrollment":50},{"nctId":"NCT07467590","phase":"PHASE2","title":"Combination of High and Low-Dose Radiotherapy With Immune Therapy and TKI in Advanced Colorectal Cancer: A Phase II Study","status":"NOT_YET_RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2026-04-01","conditions":"Refractory Colorectal Cancer, Radiotherapy-Induced Immune Priming, Immune Response","enrollment":33},{"nctId":"NCT07460362","phase":"PHASE2","title":"Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2025-08-11","conditions":"MCL, Relapsed or Refractory Mantle Cell Lymphoma (MCL)","enrollment":43},{"nctId":"NCT07446452","phase":"PHASE2","title":"Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-01-01","conditions":"HER2-low Breast Cancer","enrollment":37},{"nctId":"NCT06047379","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","status":"RECRUITING","sponsor":"Neonc Technologies, Inc.","startDate":"2023-11-01","conditions":"Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult","enrollment":134},{"nctId":"NCT01356290","phase":"PHASE2","title":"Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2014-04","conditions":"Medulloblastoma Recurrent, Ependymoma Recurrent, ATRT Recurrent","enrollment":232},{"nctId":"NCT07335497","phase":"PHASE1, PHASE2","title":"CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Crescent Biopharma, Inc.","startDate":"2026-02-17","conditions":"Locally Advanced / Metastatic Solid Tumors","enrollment":290},{"nctId":"NCT04704921","phase":"PHASE2, PHASE3","title":"Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD","status":"RECRUITING","sponsor":"AbbVie","startDate":"2020-12-29","conditions":"AMD, nAMD, Wet Age-related Macular Degeneration","enrollment":630},{"nctId":"NCT03851614","phase":"PHASE2","title":"Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2019-04-08","conditions":"Mismatch Repair Proficient Colorectal Cancer, Pancreatic Adenocarcinoma, Leiomyosarcoma","enrollment":90},{"nctId":"NCT05673824","phase":"PHASE2","title":"Effect of Huaier Granule on Nephrotoxicity Associated With Targeted Therapy for Advanced Hepatobiliary Malignancies.","status":"COMPLETED","sponsor":"Fudan University","startDate":"2023-01-03","conditions":"Nephrotoxicity","enrollment":76},{"nctId":"NCT06662006","phase":"PHASE2","title":"Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2024-03-01","conditions":"Advanced Metastatic Pancreatic Cancer","enrollment":56},{"nctId":"NCT07389876","phase":"","title":"Albumin-bound Paclitaxel-based Second-line Treatment Regimens for Locally Advanced or Metastatic G/GEJ Adenocarcinoma","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-09-01","conditions":"Gastric Cancer, Second-line Treatment","enrollment":250},{"nctId":"NCT04787341","phase":"PHASE2","title":"PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2020-12-15","conditions":"Colorectal Cancer","enrollment":214},{"nctId":"NCT01391962","phase":"PHASE2","title":"Sunitinib or Cediranib for Alveolar Soft Part Sarcoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-07-18","conditions":"Sarcoma, Alveolar Soft Part","enrollment":34},{"nctId":"NCT07375901","phase":"NA","title":"the Blood-Aqeous Barrier During Anti-Angiogenic Therapy in Exudative Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"The Filatov Institute of Eye Diseases and Tissue Therapy","startDate":"2021-03-25","conditions":"AMD","enrollment":30},{"nctId":"NCT07371910","phase":"PHASE3","title":"Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-06-12","conditions":"Metastatic Breast Cancer, HRD-Positive/HER2-Negative Advanced Breast Cancer","enrollment":200},{"nctId":"NCT06264531","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Anti-angiogenic Therapy With IV Bevacizumab in Patients With Symptomatic Cerebral Arteriovenous Malformations","status":"RECRUITING","sponsor":"Fondation Ophtalmologique Adolphe de Rothschild","startDate":"2026-01-16","conditions":"Cerebral AV Malformation","enrollment":54},{"nctId":"NCT07359053","phase":"PHASE2","title":"MAGNATE-S: Paclitaxel Polymer Micelles Combo in Advanced Sarcoma","status":"RECRUITING","sponsor":"Shanghai 6th People's Hospital","startDate":"2025-12-25","conditions":"Sarcoma","enrollment":46},{"nctId":"NCT07355361","phase":"PHASE2","title":"Huaier Granule and Proteinuria","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-01-15","conditions":"Proteinuria, Breast Cancer Patients","enrollment":120},{"nctId":"NCT05984927","phase":"PHASE1, PHASE2","title":"NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration","status":"ACTIVE_NOT_RECRUITING","sponsor":"Elisigen, Inc.","startDate":"2023-09-08","conditions":"Age-Related Macular Degeneration","enrollment":20},{"nctId":"NCT07353827","phase":"PHASE2","title":"FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-01","conditions":"Intrahepatic Cholangiocarcinoma (Icc), Hepatic Arterial Infusion Chemotherapy","enrollment":36},{"nctId":"NCT07314372","phase":"PHASE2","title":"FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2026-02-01","conditions":"Unresectable Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma (HCC), Liver Cancer Adult","enrollment":86},{"nctId":"NCT07307443","phase":"PHASE2","title":"A Phase II Study of Anlotinib and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Lung Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Zhijie Wang","startDate":"2026-02-01","conditions":"SMARCA4-Deficient Tumor, Locally Advanced or Metastatic Lung Cancer","enrollment":28},{"nctId":"NCT06562673","phase":"PHASE1, PHASE2","title":"Intra-arterial Cisplatin Plus Rh-endostatin Combined With Systematic Chemotherapy in Osteosarcoma","status":"COMPLETED","sponsor":"Shanghai 6th People's Hospital","startDate":"2024-12-03","conditions":"Osteosarcoma, Bone Cancer","enrollment":10},{"nctId":"NCT07272512","phase":"PHASE4","title":"Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-11-11","conditions":"Neuroendocrine Tumors, Neuroendocrine Neoplasms","enrollment":350},{"nctId":"NCT07293819","phase":"","title":"Comprehensive Assessment of First Trimester Pregnancy Loss","status":"RECRUITING","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2025-10-02","conditions":"Miscarriage in First Trimester","enrollment":225},{"nctId":"NCT04566185","phase":"NA","title":"Evaluation of the Predictive Value of 18F-fluorodeoxyglucose Positron Emission Tomography and Brain Perfusion Computed Tomography for the Efficacy of Anti-angiogenic Therapy (Bevacizumab) in Recurrent Glioblastoma","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2020-12-16","conditions":"Glioblastoma","enrollment":14},{"nctId":"NCT01871766","phase":"PHASE2","title":"Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-12-04","conditions":"Rhabdomyosarcoma","enrollment":115},{"nctId":"NCT03307785","phase":"PHASE1","title":"Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042","status":"COMPLETED","sponsor":"Tesaro, Inc.","startDate":"2017-10-12","conditions":"Neoplasms, Metastatic Cancer, Advanced Cancer","enrollment":60},{"nctId":"NCT07231575","phase":"PHASE2","title":"Neoadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resectable EGFR Wild-type NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-11-10","conditions":"Neoadjuvant Immunotherapy, NSCLC, Chemo-free Therapy","enrollment":39},{"nctId":"NCT05142189","phase":"PHASE1","title":"Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2022-06-17","conditions":"Non-Small Cell Lung Cancer","enrollment":280},{"nctId":"NCT07206511","phase":"","title":"Conversion Therapy Using TACE/HAIC With Anti-Angiogenic and Immunotherapy for Initially Unresectable Hepatocellular Carcinoma Achieving Complete Response or Resectability, Followed by Surgery or Continued Systemic Treatment: A Prospective Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-10-09","conditions":"Unresectable Hepatocellular Carcinom","enrollment":278},{"nctId":"NCT04877821","phase":"PHASE2","title":"The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2021-09-15","conditions":"Triple Negative Breast Cancer","enrollment":31},{"nctId":"NCT07050563","phase":"NA","title":"Clinical Evaluation of the Tiaoshen Anti-Cancer Regimen in Treating Psycho-Neurological Symptom Cluster in Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Municipal Hospital of Traditional Chinese Medicine","startDate":"2025-10-06","conditions":"Cancer, Cancer Symptom Clusters","enrollment":316},{"nctId":"NCT05407636","phase":"PHASE3","title":"Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD","status":"RECRUITING","sponsor":"AbbVie","startDate":"2022-01-13","conditions":"AMD, nAMD, Wet Age-related Macular Degeneration","enrollment":660},{"nctId":"NCT04520048","phase":"NA","title":"Vascular Biomarkers Predictive of the Progression From Hypertensive Disorders in Pregnancy to Preeclampsia in Pregnant Women","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-08-11","conditions":"Hypertension Disorders in Pregnancy, Gestational Hypertension, Pre-Eclampsia","enrollment":110},{"nctId":"NCT07014137","phase":"PHASE2","title":"A Trial of ABSK043, an Oral PD-L1 Inhibitor, in Patients With Angiogenic Sarcomas","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2025-09-09","conditions":"Sarcoma","enrollment":20},{"nctId":"NCT07151209","phase":"PHASE2","title":"Immunotherapy Combined With Anti-angiogenic Therapy and Chemotherapy for Potentially Resectable MSI-H, dMMR Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-09","conditions":"Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":20},{"nctId":"NCT07150208","phase":"PHASE2","title":"T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-09","conditions":"Breast Cancer With Brain Metastasis, HER2-low Expressing Breast Cancer","enrollment":140},{"nctId":"NCT07148427","phase":"PHASE2","title":"Immunotherapy Combined With Anti-angiogenic Therapy and Chemotherapy for Gastric/Gastroesophageal Junction Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-09-20","conditions":"Gastric/Gastroesophageal Junction Adenocarcinoma","enrollment":40},{"nctId":"NCT07134101","phase":"PHASE2","title":"Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer (SMARTi-RC01)","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-09-01","conditions":"Colorectal Cancer (Diagnosis)","enrollment":138},{"nctId":"NCT07144865","phase":"NA","title":"Biological Changes in Fibrovascular Membranes of Patients With Proliferative Diabetic Retinopathy Following Faricimab Injection","status":"COMPLETED","sponsor":"Bojie Hu","startDate":"2024-12-01","conditions":"Proliferative Diabetic Retinopathy","enrollment":8},{"nctId":"NCT07143760","phase":"","title":"Topical Hyaluronic Acid Adjunctive Effects on Healing After Free Gingival Grafting in Smokers and Non-Smokers","status":"COMPLETED","sponsor":"Istanbul University","startDate":"2018-01-01","conditions":"Recession, Gingival, Tissue Grafts","enrollment":80},{"nctId":"NCT06867822","phase":"PHASE1","title":"Trial of ProAgio in Advanced/Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-07-17","conditions":"Advanced Colorectal Cancer, Metastatic Colorectal Cancer","enrollment":27},{"nctId":"NCT07134218","phase":"PHASE2, PHASE3","title":"Neoadjuvant Chemoradiotherapy Combined With Immunotherapy and Anti-angiogenesis in Treating Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Changhai Hospital","startDate":"2025-10","conditions":"Rectal Cancer","enrollment":180},{"nctId":"NCT07117643","phase":"NA","title":"Ischemic Preconditioning - Perspectives of Use Vivio/in Vitro Studies","status":"ENROLLING_BY_INVITATION","sponsor":"Gdansk University of Physical Education and Sport","startDate":"2025-01-01","conditions":"Sport Medicine, Sport, Physiological Adaptations","enrollment":250},{"nctId":"NCT04069273","phase":"PHASE2","title":"Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma","status":"RECRUITING","sponsor":"Harry H Yoon","startDate":"2020-12-01","conditions":"Gastric Cancer, GastroEsophageal Cancer, Adenocarcinoma","enrollment":58},{"nctId":"NCT07083375","phase":"PHASE2","title":"A Phase II Study of QL1706 With Anti-angiogenesis Therapy and Chemotherapy in Extensive-stage Small Cell Lung Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Zhijie Wang","startDate":"2025-08-01","conditions":"Extensive Small Cell Lung Cancer","enrollment":56},{"nctId":"NCT07064902","phase":"PHASE2","title":"Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-08-01","conditions":"Nasopharyngeal Carcinoma (NPC)","enrollment":48},{"nctId":"NCT04879368","phase":"PHASE3","title":"RegoNivo vs Standard of Care Chemotherapy in AGOC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2021-06-01","conditions":"Gastro-Oesophageal Cancer","enrollment":450},{"nctId":"NCT04493203","phase":"PHASE2","title":"Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma","status":"COMPLETED","sponsor":"Yana Najjar","startDate":"2020-12-18","conditions":"Advanced Melanoma, Unresectable Melanoma","enrollment":31},{"nctId":"NCT07065435","phase":"PHASE2","title":"RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-01-01","conditions":"HER2 + Breast Cancer","enrollment":74},{"nctId":"NCT06379087","phase":"PHASE2","title":"Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC","status":"RECRUITING","sponsor":"Ji Yongling","startDate":"2024-05-01","conditions":"Non-Small Cell Lung Cancer","enrollment":20},{"nctId":"NCT07025174","phase":"PHASE2","title":"Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-06-01","conditions":"Bile Duct Carcinoma, Gall Bladder Cancer, Biliary Tract Cancer","enrollment":60},{"nctId":"NCT03762018","phase":"PHASE3","title":"BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2019-04-30","conditions":"Pleural Mesothelioma Malignant Advanced","enrollment":401},{"nctId":"NCT07003022","phase":"PHASE2","title":"Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-06-01","conditions":"Colo-rectal Cancer, MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers","enrollment":40},{"nctId":"NCT03406780","phase":"PHASE2","title":"A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy","status":"COMPLETED","sponsor":"Capricor Inc.","startDate":"2018-04-04","conditions":"Muscular Dystrophies, Muscular Dystrophy, Duchenne, Muscular Disorders, Atrophic","enrollment":20},{"nctId":"NCT05482516","phase":"PHASE3","title":"Evaluating Novel Therapies in ctDNA Positive GI Cancers","status":"RECRUITING","sponsor":"Georgetown University","startDate":"2023-03-29","conditions":"Colon Adenocarcinoma, Rectal Adenocarcinoma, Gastric Adenocarcinoma","enrollment":20},{"nctId":"NCT06965231","phase":"PHASE2","title":"Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-01-01","conditions":"Melanoma of Skin, Acral Melanoma, Stage II Melanoma","enrollment":58},{"nctId":"NCT06878625","phase":"PHASE2","title":"A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-12-06","conditions":"Evaluating the Efficacy of Trop-2 ADC Combination Therapy in Advanced Triple-Negative Breast Cancer","enrollment":138},{"nctId":"NCT06890871","phase":"PHASE1, PHASE2","title":"Radiotherapy with Immunotherapy and Anti-Angiogenic Therapy for Advanced HER2-Negative Breast Cancer: a Single-Arm Study","status":"ENROLLING_BY_INVITATION","sponsor":"Zhongnan Hospital","startDate":"2024-08-08","conditions":"Breast Cancer, Metastatic Breast Cancer","enrollment":25},{"nctId":"NCT05003245","phase":"PHASE3","title":"Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD","status":"COMPLETED","sponsor":"Shanghai Henlius Biotech","startDate":"2021-11-01","conditions":"Age Related Macular Degeneration","enrollment":407},{"nctId":"NCT06884345","phase":"PHASE1, PHASE2","title":"METR-NK Cells in Combination With Anti-angiogenic Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Anhui Provincial Cancer Hospital","startDate":"2025-03-13","conditions":"Ovarian Cancer","enrollment":28},{"nctId":"NCT06867432","phase":"PHASE2","title":"Efficacy and Safety of Yttrium-90 Microspheres Selective Internal Radiotherapy Combined with Immune Checkpoint Inhibitors and Anti-angiogenesis Drugs Sequential HAIC for Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-03-01","conditions":"Hepatocellular Carcinoma","enrollment":20},{"nctId":"NCT06858956","phase":"","title":"Real-World Study of Chidamide Combined With PD-(L)1 Inhibitors and Anti-Angiogenic Therapy for Advanced MSS-Type Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-03-01","conditions":"Colorectal Cancer","enrollment":200},{"nctId":"NCT00942877","phase":"PHASE2","title":"Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-07-18","conditions":"Sarcoma, Alveolar Soft Part","enrollment":53},{"nctId":"NCT06851299","phase":"PHASE2","title":"The Clinical Study of the Efficacy and Safety of Trop2-ADC Monotherapy or Combination Immunotherapy Strategy in the Treatment of Advanced Triple-negative Breast Cancer.","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-03-01","conditions":"Metastatic Triple-negative Breast Cancer","enrollment":60},{"nctId":"NCT06849492","phase":"PHASE2","title":"HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-04-01","conditions":"Advanced Triple Negative Breast Cancer","enrollment":120},{"nctId":"NCT06838546","phase":"PHASE2","title":"A Multicenter, Open Phase IIb Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tasly Biopharmaceuticals Co., Ltd.","startDate":"2025-02-24","conditions":"Advanced Colorectal Cancer","enrollment":80},{"nctId":"NCT04623671","phase":"PHASE2","title":"Intravenous Infusion of CAP-1002 in Patients With COVID-19","status":"COMPLETED","sponsor":"Capricor Inc.","startDate":"2020-11-15","conditions":"Covid19","enrollment":55},{"nctId":"NCT04492033","phase":"PHASE1, PHASE2","title":"A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients","status":"TERMINATED","sponsor":"Handok Inc.","startDate":"2020-06-22","conditions":"P1b: Advanced Solid Tumors, P2: Biliary Tract Cancer","enrollment":41},{"nctId":"NCT06728852","phase":"PHASE2","title":"Efficacy and Safety of Vorolanib Monotherapy As Third-line or Later Treatment for Advanced Non-small Cell Lung Cancer Patients: a Single-arm, Prospective, Open-label Phase II Clinical Study","status":"RECRUITING","sponsor":"Li-kun Chen","startDate":"2024-12-01","conditions":"Advanced Non-small Cell Lung Cancer (NSCLC), Recurrent or Metastatic Lung Cancer, Third-line and Beyond Therapy","enrollment":32},{"nctId":"NCT04844619","phase":"PHASE1","title":"KDR2-2 Suspension Eyedrop in the Treatment of Neovascular Glaucoma (KDR-NVG) Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2021-04-19","conditions":"Neovascular Glaucoma, Neovascularization","enrollment":40},{"nctId":"NCT06724263","phase":"PHASE2","title":"A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Tasly Biopharmaceuticals Co., Ltd.","startDate":"2024-12","conditions":"Recurrent Platinum-resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Cervical Cancers","enrollment":120},{"nctId":"NCT06496971","phase":"PHASE3","title":"A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients","status":"RECRUITING","sponsor":"NaviFUS Corporation","startDate":"2024-11-08","conditions":"Glioblastoma Multiforme, Glioblastoma, Glioblastoma Multiforme, Adult","enrollment":32},{"nctId":"NCT06682247","phase":"","title":"A Real-world Study of Chidamide in Combination with PD-1/PD-L1 Antibodies and Anti-angiogenic Agents in Advanced MSS Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Feng Wang","startDate":"2024-11-15","conditions":"Colorectal Cancer Metastatic","enrollment":200},{"nctId":"NCT06646198","phase":"PHASE2","title":"TIPS Plus Half-dose Donafenib in AHCC with PVTT-associated Portal Hypertension","status":"RECRUITING","sponsor":"Fei Gao","startDate":"2024-10-08","conditions":"Hepatocellular Carcinoma with PVTT","enrollment":40},{"nctId":"NCT04952571","phase":"PHASE2","title":"Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients with Recurrent Glioblastoma (GBM)","status":"TERMINATED","sponsor":"Beijing Sanbo Brain Hospital","startDate":"2021-06-27","conditions":"Recurrent Glioblastoma","enrollment":3},{"nctId":"NCT01621568","phase":"PHASE2","title":"Sunitinib for Advanced Thymus Cancer Following Earlier Treatment","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2012-05-15","conditions":"Thymoma, Thymus Neoplasms","enrollment":56},{"nctId":"NCT06603974","phase":"NA","title":"The Efficacy and Safety of Benmelstobart for GC/EGC","status":"NOT_YET_RECRUITING","sponsor":"Xijing Hospital","startDate":"2024-10-16","conditions":"Gastric Cancer","enrollment":48},{"nctId":"NCT06183762","phase":"","title":"A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer","status":"RECRUITING","sponsor":"Hunan Province Tumor Hospital","startDate":"2020-01-01","conditions":"Advanced Lung Cancer","enrollment":200},{"nctId":"NCT06597045","phase":"","title":"BIOMARKER and IMAGING CHARACTERISATION of INFLAMMATORY ATHEROMA in PATIENTS RECEIVING IMMUNOTHERAPY and ANGIOGENESIS INHIBITORS","status":"ACTIVE_NOT_RECRUITING","sponsor":"NHS Greater Glasgow and Clyde","startDate":"2022-08-30","conditions":"Cancer, Cardiotoxicity, Atherosclerotic Disease","enrollment":60},{"nctId":"NCT05664815","phase":"PHASE2","title":"Human Amniotic Membrane (hAM) for Stage II Maxillomandibular Osteonecrosis Management","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2023-09-22","conditions":"Osteonecrosis Due to Drugs, Jaw","enrollment":66},{"nctId":"NCT06563947","phase":"PHASE2","title":"Single Arm Clinical Trial (Gut Microbiota and HCC)","status":"NOT_YET_RECRUITING","sponsor":"Xu Yong, MD","startDate":"2024-08-24","conditions":"Liver Cancer","enrollment":30},{"nctId":"NCT06550752","phase":"PHASE1, PHASE2","title":"Erectile Dysfunction Treatment Using Stem Cells","status":"NOT_YET_RECRUITING","sponsor":"COR clinic of Regenerative Medicine","startDate":"2024-08-10","conditions":"Erectile Dysfunction","enrollment":30},{"nctId":"NCT06549907","phase":"","title":"A Biomarker Exploratory Study of Dual Blockade of PD1/PDL1 and CTLA4 and Anti-angiogenic Therapy","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2024-01-10","conditions":"MSS Metastatic Colorectal Cancers, MSI Solid Tumors Refractory to PD1/PDL1 Antibody Monotherapy","enrollment":50},{"nctId":"NCT06543836","phase":"PHASE2","title":"ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-12-01","conditions":"Metastatic Colorectal Cancer","enrollment":68},{"nctId":"NCT03417895","phase":"PHASE2","title":"SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2018-04-20","conditions":"Small-cell Lung Cancer","enrollment":59},{"nctId":"NCT06537505","phase":"PHASE2","title":"A Study of Microwave Ablation Combined With Immunotherapy ± Anti-angiogenic Drugs in the Treatment of Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Beidahuang Industry Group General Hospital","startDate":"2024-08-05","conditions":"Solid Tumor","enrollment":60},{"nctId":"NCT06482801","phase":"PHASE2","title":"Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2024-06-10","conditions":"Liver Cancer, Antibody","enrollment":90},{"nctId":"NCT04518852","phase":"PHASE2","title":"TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC","status":"COMPLETED","sponsor":"Sichuan Cancer Hospital and Research Institute","startDate":"2020-09-14","conditions":"Hepatocellular Carcinoma, Liver Neoplasms, Digestive System Neoplasms","enrollment":27},{"nctId":"NCT06470178","phase":"","title":"A Real-World Study of Neoadjuvant/Conversion Therapy for Colorectal Cancer With Chemotherapy And Anti-Angiogenic Targeted Agents","status":"NOT_YET_RECRUITING","sponsor":"Wuhan University","startDate":"2025-05-01","conditions":"Colorectal Cancer","enrollment":70},{"nctId":"NCT06464601","phase":"","title":"A Real-World Study of Neoadjuvant/Conversion Therapy for Locally Advanced or Metastatic Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Wuhan University","startDate":"2025-04-01","conditions":"Gastric Cancer","enrollment":70},{"nctId":"NCT04172571","phase":"PHASE2","title":"A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC)","status":"COMPLETED","sponsor":"Akeso","startDate":"2018-11-22","conditions":"Hepatocellular Carcinoma","enrollment":31},{"nctId":"NCT04625907","phase":"PHASE1, PHASE2","title":"FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2020-09-17","conditions":"Rhabdomyosarcoma","enrollment":1672},{"nctId":"NCT06423144","phase":"","title":"PD-1/PD-L1 Inhibitors and Anti-angiogenic Therapy Combined With/Without TACE/HAIC in Patients With BCLC B/C Hepatocellular Carcinoma Beyond Up-to-7","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-05","conditions":"Hepatocellular Carcinoma","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3906,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"Anti-angiogenesis","genericName":"Anti-angiogenesis","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF) Used for Treatment of various cancers.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}